NASDAQ:SMMT - SUMMIT THERAPEU/S Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.72 +0.01 (+0.58 %) (As of 05/21/2019 04:00 PM ET)Previous Close$1.71Today's Range$1.64 - $1.721852-Week Range$1.10 - $14.12Volume9,813 shsAverage Volume53,627 shsMarket Capitalization$23.81 millionP/E Ratio2.05Dividend YieldN/ABeta1.42 ProfileAnalyst RatingsChartEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat rare and infectious diseases in the United Kingdom and North America. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). The company's lead DMD product candidate is ezutromid, an orally administered small molecule, which is in Phase II clinical trial; and lead CDI product candidate is ridinilazole, an orally administered small molecule antibiotic that has completed Phase II clinical trials. It has strategic alliance with the University of Oxford to develop utrophin modulators. The company was formerly known as Summit Corporation plc and changed its name to Summit Therapeutics plc in February 2015. Summit Therapeutics plc was founded in 2003 and is based in Abingdon, the United Kingdom. Receive SMMT News and Ratings via Email Sign-up to receive the latest news and ratings for SMMT and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SMMT Previous Symbol CUSIPN/A CIK1599298 Webwww.summitplc.com Phone44-12-3544-3939Debt Debt-to-Equity RatioN/A Current Ratio3.63 Quick Ratio3.63Price-To-Earnings Trailing P/E Ratio2.05 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$56.50 million Price / Sales0.42 Cash Flow$1.1944 per share Price / Cash Flow1.44 Book Value$4.08 per share Price / Book0.42Profitability EPS (Most Recent Fiscal Year)$0.84 Net Income$9.99 million Net Margins17.27% Return on Equity29.15% Return on Assets13.05%Miscellaneous Employees61 Outstanding Shares13,844,000Market Cap$23.81 million Next Earnings Date6/4/2019 (Estimated) OptionableOptionable SUMMIT THERAPEU/S (NASDAQ:SMMT) Frequently Asked Questions What is SUMMIT THERAPEU/S's stock symbol? SUMMIT THERAPEU/S trades on the NASDAQ under the ticker symbol "SMMT." How were SUMMIT THERAPEU/S's earnings last quarter? SUMMIT THERAPEU/S (NASDAQ:SMMT) posted its earnings results on Wednesday, March, 27th. The company reported ($0.35) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.22) by $0.13. The company earned $0.66 million during the quarter, compared to the consensus estimate of $4.44 million. SUMMIT THERAPEU/S had a net margin of 17.27% and a return on equity of 29.15%. View SUMMIT THERAPEU/S's Earnings History. When is SUMMIT THERAPEU/S's next earnings date? SUMMIT THERAPEU/S is scheduled to release their next quarterly earnings announcement on Tuesday, June 4th 2019. View Earnings Estimates for SUMMIT THERAPEU/S. What price target have analysts set for SMMT? 7 Wall Street analysts have issued 12-month price targets for SUMMIT THERAPEU/S's shares. Their predictions range from $2.00 to $4.00. On average, they expect SUMMIT THERAPEU/S's share price to reach $3.00 in the next year. This suggests a possible upside of 74.4% from the stock's current price. View Analyst Price Targets for SUMMIT THERAPEU/S. What is the consensus analysts' recommendation for SUMMIT THERAPEU/S? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SUMMIT THERAPEU/S in the last year. There are currently 5 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for SUMMIT THERAPEU/S. Has SUMMIT THERAPEU/S been receiving favorable news coverage? News coverage about SMMT stock has been trending somewhat positive this week, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. SUMMIT THERAPEU/S earned a news impact score of 1.3 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the next several days. Who are some of SUMMIT THERAPEU/S's key competitors? Some companies that are related to SUMMIT THERAPEU/S include Iterum Therapeutics (ITRM), Zafgen (ZFGN), Catabasis Pharmaceuticals (CATB), Processa Pharmaceuticals (PCSA), Relmada Therapeutics (RLMD), Neurotrope (NTRP), Neos Therapeutics (NEOS), Infinity Pharmaceuticals (INFI), Otonomy (OTIC), Entasis Therapeutics (ETTX), Sunesis Pharmaceuticals (SNSS), vTv Therapeutics (VTVT), Merrimack Pharmaceuticals (MACK), Vaccinex (VCNX) and Avenue Therapeutics (ATXI). What other stocks do shareholders of SUMMIT THERAPEU/S own? Based on aggregate information from My MarketBeat watchlists, some companies that other SUMMIT THERAPEU/S investors own include Summit Therapeutics (SUMM), Sarepta Therapeutics (SRPT), Energy Transfer LP Unit (ET), Catabasis Pharmaceuticals (CATB), Sorrento Therapeutics (SRNE), CBL & Associates Properties (CBL), SandRidge Permian Trust (PER), SunCoke Energy Partners (SXCP), Cornerstone Total Return Fund (CRF) and Dynavax Technologies (DVAX). Who are SUMMIT THERAPEU/S's key executives? SUMMIT THERAPEU/S's management team includes the folowing people: Mr. Glyn O. Edwards, CEO & Exec. Director (Age 63)Prof. David Roblin, COO, Chief Medical Officer and Pres of R&D (Age 53)Prof. Kay Davies, Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor (Age 69)Ms. Melissa Strange FCCA, VP of Fin. & Company Sec. (Age 39)Ms. Michelle Avery, Director of Investor Relations When did SUMMIT THERAPEU/S IPO? (SMMT) raised $40 million in an initial public offering on Thursday, March 5th 2015. The company issued 3,500,000 shares at $11.54 per share. JMP Securities and Oppenheimer & Co. served as the underwriters for the IPO and Needham was co-manager. Who are SUMMIT THERAPEU/S's major shareholders? SUMMIT THERAPEU/S's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Acadian Asset Management LLC (1.27%) and Renaissance Technologies LLC (0.55%). Which institutional investors are selling SUMMIT THERAPEU/S stock? SMMT stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC. Which institutional investors are buying SUMMIT THERAPEU/S stock? SMMT stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. How do I buy shares of SUMMIT THERAPEU/S? Shares of SMMT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is SUMMIT THERAPEU/S's stock price today? One share of SMMT stock can currently be purchased for approximately $1.72. How big of a company is SUMMIT THERAPEU/S? SUMMIT THERAPEU/S has a market capitalization of $23.81 million and generates $56.50 million in revenue each year. The company earns $9.99 million in net income (profit) each year or $0.84 on an earnings per share basis. SUMMIT THERAPEU/S employs 61 workers across the globe. What is SUMMIT THERAPEU/S's official website? The official website for SUMMIT THERAPEU/S is http://www.summitplc.com. How can I contact SUMMIT THERAPEU/S? SUMMIT THERAPEU/S's mailing address is 136a Eastern Avenue Milton Park, Abingdon X0, OX144SB. The company can be reached via phone at 44-12-3544-3939 or via email at [email protected] MarketBeat Community Rating for SUMMIT THERAPEU/S (NASDAQ SMMT)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 215 (Vote Outperform)Underperform Votes: 208 (Vote Underperform)Total Votes: 423MarketBeat's community ratings are surveys of what our community members think about SUMMIT THERAPEU/S and other stocks. Vote "Outperform" if you believe SMMT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SMMT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/21/2019 by MarketBeat.com StaffFeatured Article: What is Depreciation? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.